spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Norwich Pharmaceuticals Announces Significant Business Growth

Norwich Clinical Services

Increased project volume, new clients propel revenues and expanded services

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.

"Norwich’s growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."

New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating, formulation development, BA/BE studies, and global packaging and distribution.

About Norwich Pharmaceuticals

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for more information.

phone +1 888 674 7979
email info@norwichpharma.com
web www.norwichpharma.com
email 6826 State Highway 12, Norwich, NY 13815, UNITED STATES
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Novartis Lung Cancer Drug Zykadia™ Recommended for EU Approval in Patients With ALK+ NSCLC

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
More info >>


White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

Industry Events

BIO-Europe Spring®

9-11 March 2015, Paris, France

The ninth annual BIO-Europe Spring® conference is the premier springtime partnering conference, to be held in Paris, France on March 9-11, 2015.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement